Skip to main content

Table 3 Incidence of treatment-emergent adverse eventsa

From: Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial

Incidence, n(%) Placebo (n= 50) Milnacipran (n= 100)
Patients with ≥1 TEAE 29 (58) 47 (47)
Nausea 1 (2) 4 (4)
Headache 0 4 (4)
Vomiting 1 (2) 4 (4)
Sinusitis 3 (6) 4 (4)
Upper respiratory tract infection 2 (4) 4 (4)
Fatigue 1 (2) 4 (4)
Pain in extremity 1 (2) 4 (4)
Fall 0 4 (4)
Arthralgia 1 (2) 3 (3)
Fibromyalgia 1 (2) 3 (3)
Peripheral edema 3 (6) 2 (2)
Hypothyroidism 2 (4) 1 (1)
Influenza 2 (4) 1 (1)
Irritability 3 (6) 0
Neck pain 2 (4) 0
  1. aReported in ≥3% of patients in either treatment group during the double-blind period. TEAE = treatment emergent adverse event.